Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of veliparib when given together
with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and
veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.